NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
Latest Information Update: 11 Oct 2024
Price :
$35 *
At a glance
- Drugs Erdafitinib (Primary)
- Indications Neuroblastoma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms MATCH
- 08 Oct 2024 Planned End Date changed from 1 Oct 2024 to 31 Dec 2025.
- 03 Oct 2023 Planned End Date changed from 31 Dec 2024 to 1 Oct 2024.
- 06 Jun 2023 Results (n=20), presented at the 59th Annual Meeting of the American Society of Clinical Oncology